InnoCan Pharma Corporation (CSE:INNO)

Market Cap	35.99M
Revenue (ttm)	37.64M
Net Income (ttm)	-4.50M
Shares Out	4.50M
EPS (ttm)	-1.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,000
Average Volume	1,284
Open	8.30
Previous Close	8.00
Day's Range	7.71 - 8.30
52-Week Range	6.66 - 21.00
Beta	-0.06
RSI	34.09
Earnings Date	Mar 31, 2026

About InnoCan Pharma

InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. The company operates in two segments: Online Sales and Other Operations. It engages in the research and development of CBD loaded exosomes, as well as operates LPT CBD-loaded liposome platform that facilitates exact dosing and the prolonged and controlled release of CBD into the blood stream for e...

• Industry: Household & Personal Products
• Sector: Consumer Staples
• Founded: 2018
• Employees: 5
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: INNO

Financial Performance

In 2024, InnoCan Pharma's revenue was $29.44 million, an increase of 115.55% compared to the previous year's $13.66 million. Losses were -$1.83 million, -60.98% less than in 2023.

Financial numbers in USD